Literature DB >> 30811269

Poor Control of Sarcoidosis-Related Panuveitis with an Antibody to IL-23.

Akshay S Thomas1,2, James T Rosenbaum1,3.   

Abstract

Entities:  

Year:  2019        PMID： 30811269      PMCID： PMC6711832          DOI： 10.1080/09273948.2019.1569245

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN： 0927-3948            Impact factor:   3.070


× No keyword cloud information.
  8 in total

1.  Long-term treatment with infliximab in patients with sarcoidosis.

Authors:  Katrin E Hostettler; Ueli Studler; Michael Tamm; Martin H Brutsche
Journal:  Respiration       Date:  2011-07-29       Impact factor: 3.580

2.  Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.

Authors:  Erik Letko; Steven Yeh; C Stephen Foster; Uwe Pleyer; Mitchell Brigell; Cynthia L Grosskreutz
Journal:  Ophthalmology       Date:  2015-01-29       Impact factor: 12.079

3.  Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials.

Authors:  Andrew D Dick; Ilknur Tugal-Tutkun; Stephen Foster; Manfred Zierhut; S H Melissa Liew; Vladimir Bezlyak; Sofia Androudi
Journal:  Ophthalmology       Date:  2013-01-03       Impact factor: 12.079

Review 4.  Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis.

Authors:  Kathryn L Pepple; Phoebe Lin
Journal:  Ophthalmology       Date:  2018-07-04       Impact factor: 12.079

5.  TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1.

Authors:  Ahjoku Amadi-Obi; Cheng-Rong Yu; Xuebin Liu; Rashid M Mahdi; Grace Levy Clarke; Robert B Nussenblatt; Igal Gery; Yun Sang Lee; Charles E Egwuagu
Journal:  Nat Med       Date:  2007-05-13       Impact factor: 53.440

6.  Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis.

Authors:  James P Utz; Andrew H Limper; Sanjay Kalra; Ulrich Specks; John P Scott; Zvezdana Vuk-Pavlovic; Darrell R Schroeder
Journal:  Chest       Date:  2003-07       Impact factor: 9.410

7.  Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis.

Authors:  Marc A Judson; Robert P Baughman; Ulrich Costabel; Marjolein Drent; Kevin F Gibson; Ganesh Raghu; Hidenobu Shigemitsu; Joseph B Barney; Daniel A Culver; Nabeel Y Hamzeh; Marlies S Wijsenbeek; Carlo Albera; Isham Huizar; Prasheen Agarwal; Carrie Brodmerkel; Rosemary Watt; Elliot S Barnathan
Journal:  Eur Respir J       Date:  2014-07-17       Impact factor: 16.671

8.  Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category.

Authors:  Dror Luger; Phyllis B Silver; Jun Tang; Daniel Cua; Zoe Chen; Yoichiro Iwakura; Edward P Bowman; Nicole M Sgambellone; Chi-Chao Chan; Rachel R Caspi
Journal:  J Exp Med       Date:  2008-04-07       Impact factor: 14.307
  8 in total
  4 in total

Review 1.  Identifying and Treating Ocular Manifestations in Psoriasis.

Authors:  Mahsaw Motlagh; Christopher Fortenbach; Howard I Maibach; Bobeck S Modjtahedi
Journal:  Am J Clin Dermatol       Date:  2021-11-03       Impact factor: 7.403

Review 2.  The Evolving Landscape of Cutaneous Sarcoidosis: Pathogenic Insight, Clinical Challenges, and New Frontiers in Therapy.

Authors:  Julie H Wu; Sotonye Imadojemu; Avrom S Caplan
Journal:  Am J Clin Dermatol       Date:  2022-05-18       Impact factor: 6.233

Review 3.  Emerging Molecular Targets for the Treatment of Refractory Sarcoidosis.

Authors:  Gonçalo Boleto; Matheus Vieira; Anne Claire Desbois; David Saadoun; Patrice Cacoub
Journal:  Front Med (Lausanne)       Date:  2020-11-24

Review 4.  Cytokines that Modulate the Differentiation of Th17 Cells in Autoimmune Uveitis.

Authors:  Kailei Guo; Xiaomin Zhang
Journal:  J Immunol Res       Date:  2021-03-16       Impact factor: 4.818
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.